SEARCH

SEARCH BY CITATION

References

  • 1
    Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 42734.
  • 2
    Amy D'Orazio DL. Adding a humanized antibody to vascular endothelial growth factor (bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer. Clin Colorectal Cancer 2003; 8: 858.
  • 3
    Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 605.
  • 4
    Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 5
    Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004; 10: (18 Pt 2): 6367S70S.
  • 6
    Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 103547.
  • 7
    Nguyen QD, Shah S, Tatlipinar S et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 136870.
  • 8
    Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 3369.
  • 9
    Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 2758.
  • 10
    Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 3524.
  • 11
    Nakagawa T, Kosugi T, Haneda M et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009; 58: 14718.
  • 12
    Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 4427.
  • 13
    Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 44550.
  • 14
    Tolentino MJ, McLeod DS, Taomoto M et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 37385.
  • 15
    Tolentino MJ, Miller JW, Gragoudas ES et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 18208.
  • 16
    Miller JW, Adamis AP, Aiello P. Vascular endothelial growth factor in ocular neovascularization and proliferative retinopathy. Diabetes Metab Rev 1997; 13: 3750.
  • 17
    Inhibition VEGF. Study in Ocular Neovascularization(VISION) Clinical trial group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 9921001.
  • 18
    Avery RL. Intravitreal bevacizumb (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 36372.
  • 19
    Soheilian M, Ramezani A, Bijanzadeh B et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 118795.
  • 20
    Minnella AM, Savastano CM, Ziccardi L et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008; 86: 6837.
  • 21
    Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 2629.
  • 22
    Civin C, Strauss LC, Brovall C et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 15765.
  • 23
    Fina L, Molgaard HV, Robertson D et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 241726.
  • 24
    Barth PJ, Westhoff CC. CD34+ fibrocytes: morphology, histogenesis and function. Curr. Stem Cell Res Ther 2007; 2: 2217.
  • 25
    Cui S, Hano H, Sakata A et al. Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol Int 1996; 46: 7516.
  • 26
    Jankowski RJ, Deasy BM, Cao B et al. The role of CD34 expression and cellular fusion in the regeneration capacity of myogenic progenitor cells. J Cell Sci 2002; 115 (Pt 22): 436174.
  • 27
    Joussen AM, Poulaki V, Tsujikawa A et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 2002; 160: 168393.
  • 28
    Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73: 33346.
  • 29
    Ferrara N, Damico L, Shams N et al. Developmemt of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 85970.
  • 30
    Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006; 113: 36372.
  • 31
    Yu L, Wu X, Cheng Z et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49: 5227.
  • 32
    Ferrara N, Hillan KJ, Gerber HP et al. Discovery and evelopment of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391400.
  • 33
    Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 254552.
  • 34
    Manzano RP, Peyman GA, Khan P et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 2007; 91: 8047.
  • 35
    Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49: 45237.
  • 36
    Ameri H, Chader GJ, Kim J et al. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007; 48: 570815.
  • 37
    Lassota N, Prause JU, Scherfig E et al. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin(R)) in a porcine model of choroidal neovascularization. Acta Ophthalmol 2010; 88: 3008. [Epub ahead of print.
  • 38
    Heiduschka P, Fietz H, Hofmeister S et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 281423.
  • 39
    Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009; 13: 4002.
  • 40
    Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008; 37: 5913.
  • 41
    Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695705.
  • 42
    Bakri SJ, Snyder MR, Reid JM et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 8559.
  • 43
    Velez-Montoya R, Fromow-Guerra J, Burgos O et al. The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: A pilot study. Retina 2009; 29: 206.
  • 44
    Miyake T, Sawada O, Kakinoki M et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51: 16068. [Epub ahead of print.